Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
Royalty Pharma’s $1.5 Billion Acquisition of PTC Therapeutics’ Royalties
Envisagenics’ Research Collaboration Agreement with Bristol Myers Squibb Company
Goodwin Procter advised Envisagenics, Inc. on the deal. Envisagenics, Inc. announced a research collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The multi-year collaboration will leverage...